Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Jeffrey Eisele, Chief Development Officer of Apellis Pharmaceuticals, sold 63 shares of common stock on December 23, 2024, to cover tax withholding obligations related to restricted stock units.
Summary
- On December 23, 2024, Jeffrey Eisele, the Chief Development Officer of Apellis Pharmaceuticals, sold 63 shares of the company's common stock.
- The sale was executed at a price of $33.09 per share.
- This transaction was conducted to cover tax withholding requirements associated with the release of restricted stock units on December 20, 2024.
- Following the transaction, Eisele directly owns 57,145 shares of Apellis Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an executive's stock sale to cover tax obligations. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 12/20/2024 | Restricted Stock Units released |
| 12/23/2024 | Date of stock sale transaction |
| 12/27/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.